A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Liverpool Hospital /ID# 155952, Liverpool

St George Hospital /ID# 156037, Kogarah

The Royal Melbourne Hospital /ID# 155949, Parkville

St Vincent's Hospital Melbourne /ID# 155950, Fitzroy Melbourne

Royal Perth Hospital /ID# 155951, Perth

Universitaetsklinikum Duesseldorf /ID# 154899, Düsseldorf

Marien Hospital Duesseldorf /ID# 155518, Düsseldorf

Universitaetsklinikum Koeln /ID# 155519, Cologne

Duplicate_University of Chicago /ID# 155364, Chicago

Universitatsklinikum Mannheim /ID# 156038, Mannheim

University of Texas MD Anderson Cancer Center /ID# 155362, Houston

University of Colorado Hospital /ID# 155365, Aurora

Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 154896, Munich

Oregon Health and Science University /ID# 155360, Portland

University of Arizona Cancer Center - North Campus /ID# 157503, Tucson

Yale University /ID# 162544, New Haven

Pediatric Endocrine Associates /ID# 171227, Boston

Dana-Farber Cancer Institute /ID# 155361, Boston

University of Massachusetts - Worcester /ID# 155366, Worcester

Columbia Univ Medical Center /ID# 156388, New York

Universitaetsklinikum Leipzig /ID# 154897, Leipzig

Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 154898, Dresden

Universitaetsklinikum Halle (Saale) /ID# 158643, Halle